Athira Pharma (ATHA) Competitors $0.30 +0.00 (+0.37%) Closing price 04:00 PM EasternExtended Trading$0.30 +0.00 (+1.30%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. XCUR, ADVM, ALGS, IPA, STTK, MRSN, NBRV, KLRS, MURA, and CELUShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Exicure (XCUR), Adverum Biotechnologies (ADVM), Aligos Therapeutics (ALGS), ImmunoPrecise Antibodies (IPA), Shattuck Labs (STTK), Mersana Therapeutics (MRSN), Nabriva Therapeutics (NBRV), Kalaris Therapeutics (KLRS), Mural Oncology (MURA), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors Exicure Adverum Biotechnologies Aligos Therapeutics ImmunoPrecise Antibodies Shattuck Labs Mersana Therapeutics Nabriva Therapeutics Kalaris Therapeutics Mural Oncology Celularity Exicure (NASDAQ:XCUR) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation. Do institutionals and insiders believe in XCUR or ATHA? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 22.1% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer XCUR or ATHA? In the previous week, Athira Pharma had 1 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Athira Pharma and 4 mentions for Exicure. Athira Pharma's average media sentiment score of 1.32 beat Exicure's score of 0.57 indicating that Athira Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Athira Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XCUR or ATHA more profitable? Athira Pharma's return on equity of -142.99% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -353.47% -96.50% Athira Pharma N/A -142.99%-106.40% Which has preferable valuation and earnings, XCUR or ATHA? Exicure has higher revenue and earnings than Athira Pharma. Exicure is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K75.33-$9.70M-$4.81-1.24Athira PharmaN/AN/A-$96.94M-$2.07-0.15 Which has more volatility and risk, XCUR or ATHA? Exicure has a beta of 3.57, suggesting that its share price is 257% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.99, suggesting that its share price is 199% more volatile than the S&P 500. Do analysts recommend XCUR or ATHA? Athira Pharma has a consensus price target of $11.25, indicating a potential upside of 3,636.30%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAthira Pharma beats Exicure on 9 of the 13 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.71M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.1521.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book0.267.518.055.38Net Income-$96.94M-$55.05M$3.15B$248.50M7 Day Performance-3.49%2.45%1.85%2.97%1 Month Performance5.61%7.33%4.81%6.02%1 Year Performance-88.05%5.38%34.86%20.39% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma2.8387 of 5 stars$0.30+0.4%$11.25+3,636.3%-88.0%$11.71MN/A-0.1540News CoveragePositive NewsXCURExicure1.9881 of 5 stars$6.50-13.0%N/A+1,835.9%$47.19M$500K-1.3550Earnings ReportGap DownADVMAdverum Biotechnologies4.3304 of 5 stars$2.23-0.9%$26.40+1,083.9%-67.3%$47M$1M-0.35190ALGSAligos Therapeutics4.2166 of 5 stars$7.18-4.9%$70.00+874.9%-19.9%$46.16M$3.27M-0.4190Positive NewsIPAImmunoPrecise Antibodies2.5169 of 5 stars$0.96-4.5%$4.00+316.6%+9.6%$45.99M$24.00M-0.8380Upcoming EarningsGap UpSTTKShattuck Labs3.3554 of 5 stars$1.01+5.5%$7.50+642.6%-79.6%$45.84M$4.61M-0.73100News CoverageMRSNMersana Therapeutics3.8223 of 5 stars$0.34-6.9%$5.20+1,426.7%-85.8%$45.60M$40.50M-0.58150News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070KLRSKalaris TherapeuticsN/A$2.36-1.7%N/AN/A$44.89MN/A0.00110Positive NewsGap UpMURAMural Oncology3.5399 of 5 stars$2.50+2.0%$13.00+420.0%-19.6%$42.31MN/A-0.33119Positive NewsCELUCelularity0.1379 of 5 stars$2.01+14.2%N/A-35.7%$42.15M$54.22M-0.76220News CoveragePositive NewsGap Up Related Companies and Tools Related Companies XCUR Competitors ADVM Competitors ALGS Competitors IPA Competitors STTK Competitors MRSN Competitors NBRV Competitors KLRS Competitors MURA Competitors CELU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHA Stock Alerts